News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dynogen Pharmaceuticals, Inc. Announces Positive Results in Phase 2 IBS-d Study



12/17/2007 9:03:37 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Dynogen Pharmaceuticals, Inc. today announced positive results from its Phase 2 trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d). The randomized, double-blind, placebo controlled trial generated statistically significant results for the clinical endpoint of relief from abdominal pain or discomfort associated with IBS-d. Detailed results will be submitted for disclosure in a peer-reviewed journal or at a future medical conference.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES